Clinical trial D-FR-01087-001
An international multi-center, open-label radioactivity escalation study to evaluate the safety, tolerability, biodistribution, and preliminary anti-tumor activity of 177Lu-3BP-227 for therapy in previously treated patients with advanced gastrointestinal cancers expressing neurotensin 1 receptors
| Cancers | |
|---|---|
| Organ | Germ cell tumors |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1/2 |
| Academic trial | Non |
| Sponsor | Ipsen |
| EudraCT Identifier | 2017-001263-20 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03525392 |
| Inclusion criteria | *NTSR1 expression*Measureable disease RECIST 1.1 |
| Last update |